Loading stock data…
APLS
$41.03-0.03 (-0.07%)
Market ClosedLast close May 13
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Apellis Pharmaceuticals, Inc. in the Healthcare sector is trading at $41.03. Wall Street consensus targets $40.93 (15 analysts), implying a -0.2% move over the next 12 months. The stock is currently near its 52-week high of $41.14, remaining 58.7% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$41.03
Potential Downside
95.6%
Whystock Fair Value$1.81
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus15 analysts
Hold
Mean target$40.93-0.2%
Range$40.00 – $41.00
Fundamentals
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.23B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
227.17
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.20
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-61.64%
Volume
Today's trading volume
55.80M
Recent News
Compared to Estimates, Apellis Pharmaceuticals (APLS) Q1 Earnings: A Look at Key Metrics
The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Apellis Pharmaceuticals, Inc. (APLS) Tops Q1 Earnings and Revenue Estimates
Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of +139.30% and +33.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: Should You Buy?
ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Should You Buy?
Apellis Pharmaceuticals (APLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?
Biogen heads into Q1 earnings with new drugs like Skyclarys and Zurzuvae driving growth as legacy MS products face rising competitive pressure.